|
|
|
11-50 employees
View all
|
|
pharmaceuticals
|
|
1020 East Meadow Circle,Palo Alto,CA,United States
|
|
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.
|
Anacor Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
87.5%
|
The widely used Anacor Pharmaceuticals email format is {f}{last} (e.g. [email protected]) with 87.5% adoption across the company.
To contact Anacor Pharmaceuticals customer service number in your country click here to find.
Kevin Munoz is the CEO of Anacor Pharmaceuticals. To contact Kevin Munoz email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.